Table 1. Baseline characteristics of included patients (N=78).
| Characteristics | Patients [n (%)] |
| ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hormone receptor; TOP2A, topoisomerase 2 alpha; IHC, immunohistochemistry. | |
| Age (year) [median (range)] | 49 (29−70) |
| <40 | 18 (23.1) |
| 40−50 | 27 (34.6) |
| >50 | 33 (42.3) |
| HR status | |
| Positive | 50 (64.1) |
| Negative | 28 (35.9) |
| ECOG PS 0 | 78 (100) |
| Menopausal status | |
| Premenopausal | 49 (62.8) |
| Postmenopausal | 29 (37.2) |
| Histological type | |
| Ductal carcinoma | 76 (97.4) |
| Lobular carcinoma | 2 (2.6) |
| Histological grade | |
| II | 26 (33.3) |
| II−III | 3 (3.8) |
| III | 18 (23.1) |
| Unknown | 31 (39.7) |
| Lymph node status | |
| Positive | 55 (70.5) |
| Negative | 23 (29.5) |
| Clinical stage | |
| Stage II | 55 (70.5) |
| Stage III | 23 (29.5) |
| T stage | |
| T1 | 3 (3.8) |
| T2 | 49 (62.8) |
| T3 | 23 (29.5) |
| T4 | 3 (3.8) |
| N stage | |
| N0 | 23 (29.5) |
| N1 | 45 (57.7) |
| N2 | 7 (9.0) |
| N3 | 3 (3.8) |
| TOP2A IHC expression | |
| Negative | 1 (1.3) |
| <15% | 14 (17.9) |
| 15%−30% | 31 (39.7) |
| >30% | 23 (29.5) |
| Unknown | 9 (11.5) |